Home About Us News Screening Diagnosis Treatment Patient Information Education
Contact Us
Educational Articles
Breast Cancer FAQs
Breast Self Exams
Breast Pain / Mastalgia
BRCA Testing
Fibrocystic Breast Changes
Open Breast Biopsies
Benefits of SAVI
Molecular Subtyping
Adjuvant Therapy
HALO Breast Pap Test
Inflammatory Breast Cancer
Locally Advanced Breast Cancer
Radiation Treatment for Early Stage
Sentinel Lymph Node Biopsy
Stereotactic Core Needle Biopsy
Non-Invasive Breast Cancer
No Prissy Shoes
Clinical Trials
American Society of Breast Surgery Mammo
University of Louisville Sentinel Lymph
NSABP, B39, B40 Clinical Trials
Taylor Rx Trial
Types of Breast Cancer
In Situ Breast Cancer
Invasive Breast Cancer
Locally Advanced Breast Cancer
Inflammatory Breast Cancer
Metastatic Breast Cancer
Frequently Asked Questions
What is Breast Pain/Mastalgia?
What is Lobular Carcinoma is Situ?
What is Atypical Ductal Hyperplasia?
What are Estrogen and Progesterone recep
What is the HER-2/neu test?
What is Whole Breast Irradiation?
What is Partial Breast Irradiation?
What are the reconstruction options?
Why do we give chemotherapy?
What is Tamoxifen?
What Is Ductal Carcinoma in Situ?
Are there prognostic indicators?
Are there different types?
What is Nipple Discharge?
What is Breast Cancer?
How does Breast Cancer spread?
Who gets Breast Cancer?
What are the chances?
Does race play a role in incidence?
What are fibrocystic changes?
What are the physical signs?
How is Breast Cancer staged?
What are the Aromatase inhibitors?
Are there prognostic indicators in Breast Cancer?
The most useful clinical prognostic indicators that help determine a treatment plan for women with breast cancer are tumor size, lymph node status, presence of lympho-vascular  involvement, nuclear grade, architectural grade, mitotic index, ER/PR status, and HER2/nue status. The OncotypeDx is a 21 gene array analysis of an individual’s breast cancer. It has been validated in retrospective studies done on patients who participated in the NSABP-b14 and b-20 clinical trials. This genomic test is the first of its kind and will predict the benefit of endocrine therapy and chemotherapy for a woman with breast cancer. This test has the ability to help physicians determine which patients would benefit from chemotherapy based on the individual’s breast cancer genomic make up. In the near future, this type of test will replace prognostic indicators in determining treatment options.